TrialBlood2009

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.